Geneva, Sept. 23 -- International Clinical Trials Registry received information related to the study (JPRN-jRCT2031250354) titled 'Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a) ( MOVE-Lp(a) )' on Sept. 10.
Study Type: Interventional
Study Design:
randomized controlled trial, double blind, placebo control, parallel assignment, treatment purpose
Primary Sponsor: Masaki Takeshi
Condition:
Elevated Lp(a)
Atherosclerotic Cardiovascular Disease (ASCVD)
Intervention:
Drug: Muvalaplin
Administered orally
Other Names:LY3473329
(Study Arms)
Experimental: Muvalaplin
Participants will receive muvalaplin orally....
Recruitment Status: Not Recruiting
Phase: 3
Date of First Enrollm...